GASCO, Valentina
 Distribuzione geografica
Continente #
NA - Nord America 3.957
EU - Europa 2.330
AS - Asia 1.454
SA - Sud America 178
OC - Oceania 26
AF - Africa 24
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.972
Nazione #
US - Stati Uniti d'America 3.894
IT - Italia 693
CN - Cina 546
SG - Singapore 410
SE - Svezia 326
IE - Irlanda 305
DE - Germania 216
UA - Ucraina 148
FR - Francia 136
JP - Giappone 125
FI - Finlandia 105
KR - Corea 103
BR - Brasile 102
GB - Regno Unito 93
PL - Polonia 70
VN - Vietnam 52
IN - India 41
ES - Italia 39
TR - Turchia 35
AR - Argentina 33
AT - Austria 33
CA - Canada 33
MX - Messico 28
NL - Olanda 26
BE - Belgio 25
HK - Hong Kong 25
GR - Grecia 24
RU - Federazione Russa 24
AU - Australia 22
CO - Colombia 22
ID - Indonesia 19
PH - Filippine 19
UZ - Uzbekistan 18
CH - Svizzera 14
CL - Cile 11
PT - Portogallo 10
IQ - Iraq 8
RO - Romania 8
TH - Thailandia 8
IL - Israele 7
RS - Serbia 7
DZ - Algeria 6
IR - Iran 6
OM - Oman 6
TW - Taiwan 6
PE - Perù 5
BT - Bhutan 4
CZ - Repubblica Ceca 4
EG - Egitto 4
HR - Croazia 4
LT - Lituania 4
MY - Malesia 4
NZ - Nuova Zelanda 4
AE - Emirati Arabi Uniti 3
HU - Ungheria 3
SA - Arabia Saudita 3
SI - Slovenia 3
SN - Senegal 3
TN - Tunisia 3
BY - Bielorussia 2
DK - Danimarca 2
EC - Ecuador 2
EU - Europa 2
KE - Kenya 2
LV - Lettonia 2
MU - Mauritius 2
VE - Venezuela 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
MA - Marocco 1
MQ - Martinica 1
MT - Malta 1
PK - Pakistan 1
QA - Qatar 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 7.972
Città #
Chandler 606
Santa Clara 395
Singapore 331
Beijing 306
Dublin 296
Houston 228
Ann Arbor 149
Ashburn 138
Nyköping 121
Medford 112
Turin 107
Columbus 100
Fairfield 99
Princeton 91
Redwood City 87
Torino 82
Dearborn 80
Jacksonville 78
Wilmington 78
Milan 59
Villeurbanne 59
Warsaw 55
Woodbridge 55
Seattle 41
Tokyo 39
Cambridge 37
Boardman 33
Guangzhou 31
Boston 28
Hangzhou 28
Rome 27
Vienna 25
Brussels 24
Dong Ket 22
Fremont 19
Los Angeles 19
Seoul 18
Jakarta 17
New York 17
Pisa 16
São Paulo 16
Verona 16
Chicago 13
Hebei 13
Istanbul 13
Kunming 13
Philadelphia 13
Mexico 12
Shanghai 12
Toronto 12
Barcelona 11
Detroit 11
Florence 11
London 11
Mexico City 11
Mountain View 11
Norwalk 11
Santiago 11
Bogotá 10
Munro 10
Nola 10
Ankara 9
Athens 9
Buenos Aires 9
Chengdu 9
Hefei 9
Modena 9
Munich 9
Padova 9
San Mateo 9
Helsinki 8
Lappeenranta 8
Palermo 8
Pune 8
San Diego 8
Bologna 7
Central District 7
Edison 7
Falls Church 7
Hanoi 7
Jinan 7
Lachine 7
Moscow 7
Nuremberg 7
Sydney 7
Alessandria 6
Hong Kong 6
Muscat 6
Nagoya 6
Nanchang 6
Rio De Janeiro 6
San Giuliano Milanese 6
Bangalore 5
Brescia 5
Campinas 5
Changsha 5
Genova 5
Mumbai 5
Napoli 5
Nichelino 5
Totale 4.677
Nome #
Management of GH treatment in adult GH deficiency 1.311
Involvement of hypothalamus autoimmunity in patients with autoimmune hypopituitarism: role of antibodies to hypothalamic cells. 218
HLA DRB1*0415: a new possible genetic susceptibility factor for Hirata's disease 212
Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults. 209
USEFULNESS OF AN AD HOC QUESTIONNAIRE (ACRO-CQ) FOR THE SYSTEMATIC ASSESSMENT OF ACROMEGALY COMORBIDITIES AT DIAGNOSIS AND THEIR MANAGEMENT AT FOLLOW-UP 198
Long term safety of recombinant human growth hormone (rhGH) in patients treated during childhood 138
L'ipopituitarismo post trauma cranico: dall'età pediatrica all'età adulta 122
Traumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment 107
First but not second postoperative day growth hormone assessments as early predictive tests for long-term acromegaly persistence 97
SENSITIVITY AND SPECIFICITY OF DIFFERENT PROVOCATIVE TESTS ASSESSING THE FUNCTION OF HYPOTHALAMO-PITUITARY-ADRENAL (HPA) AXIS IN PATIENTS SUSPECTED FOR SECONDARY HYPOADRENALISM 96
Pituitary-gonadal function in males with Down’s syndrome. 96
Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy 95
Acylated ghrelin as provocative test for the diagnosis of ACTH deficiency in patients with hypothalamus–pituitary disease 94
Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma 90
Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery 88
Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease. 87
Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? 86
Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood. 86
Measurement of height velocity is an useful marker for monitoring pituitary function in patients who had traumatic brain injury 86
Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients 85
Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas 83
Update on epidemiology, etiology, and diagnosis of adult growth hormone deficiency 81
Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study 81
Association of Urine Metanephrine Levels with Cardiometabolic Risk: An Observational Retrospective Study 81
Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly 80
Endocrine and metabolic actions of ghrelin 79
Cost-of-illness study in acromegalic patients in Italy. 79
Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. 78
Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population 78
Use of the Diabetes Risk Score for Opportunistic Screening of Undiagnosed Diabetes and Impaired Glucose Tolerance: The IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study 78
Diagnosis of adult GH deficiency 77
From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma 76
Diagnostica neuroendocrina del paziente obeso (alterazioni neuroendocrine nel paziente obeso) 76
COMPARISON BETWEEN ITT, METYRAPONE AND ACTH STIMULATION WITH HIGH, LOW AND VERY LOW DOSES FOR DIAGNOSIS OF SECONDARY HYPOADRENALISM 76
Hypopituitarism following brain injury: when does it occur and how best to test? 76
Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency. 75
Early copeptin determination allows prompt diagnosis of post-neurosurgical central diabetes insipidus 75
Acromegaly and joint pain: is there something more? A cross-sectional study to evaluate rheumatic disorders in growth hormone secreting tumor patients 74
Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diThree-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. 72
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index 71
L-Arginine 70
Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study 69
Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment 68
Pegvisomant in acromegaly: why, when, how. 67
Development and Internal Validation of a Predictive Model for Adult GH Deficiency Prior to Stimulation Tests 67
Retesting the childhood-onset GH-deficient patient 66
Acromegalia e gravidanza: quali rischi per la madre e per il feto 66
Functioning and non-functioning pituitary adenomas in 173 adult and elderly patients 66
THE CUT-OFF LIMITS OF GH RESPONSE TO INSULIN TOLERANCE TEST RELATED TO BODY MASS INDEX FOR THE DIAGNOSIS OF ADULT GH DEFICIENCY 66
Ghrelin and anterior pituitary function 65
Association of craniopharyngioma and pituitary adenoma. 64
The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend? 63
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous medical Education) Study Group. 62
Second-Day Morning Cortisol Levels after Transsphenoidal Surgery Are Accurate Predictors of Secondary Adrenal Insufficiency with Diagnostic Cut-Offs Similar to Those in Non-Stressed Conditions 62
Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor 60
Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche 60
Ghrelin in the regulation of GH secretion and other pituitary hormones. 60
Impatto socio economico dei trattamenti 58
GH but not IGF-I hypersecretion in acromegaly is generally attenuated in elderly acromegalics. 57
MORNING SERUM CORTISOL LEVEL PREDICTS CENTRAL ADRENAL INSUFFICIENCY DIAGNOSED BY INSULIN TOLERANCE TEST 57
Sindrome della sella vuota 56
Hormonal diagnosis of GH hypersecretory states. 55
Evaluation of GH deficiency by GHRH+arginine test and IGF-I levels in a large population of young, middle-aged and elderly patients who had undergone neurosurgery for tumor masses in the hypothalamus-pituitary area. 54
Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease 53
Primary pituitary lymphoma as rare cause of a pituitary mass and hypopituitarism in adulthood 53
Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test 53
Premature Pubarche 51
Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI). 51
Identifying Patients at Risk for Microalbuminuria via Interaction of the Components of the Metabolic Syndrome: A Cross-Sectional Analytic Study 51
Disordini dell'accrescimento e dello sviluppo puberale 50
Malattie ipotalamo-ipofisarie: Ipopituitarismo 50
Ruolo del surrene nelle varie fasi dello sviluppo puberale 49
Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. 48
Metabolic alterations in patients who develop traumatic brain injury (TBI)-induced hypopituitarism 48
Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia? 45
Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study 45
Adrenocortical, somatotropic, and antidiuretic response to nasal glucagon in healthy subjects. 45
GH therapy in adult GH deficiency: a review of treatment schedules and the evidence for low starting doses. 45
Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study 44
Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study 43
Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency 41
Endocrine dysfunction in patients operated on for non-pituitary intracranial tumors 41
Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients 38
ONCE UPON A TIME: THE GLUCAGON STIMULATION TEST IN DIAGNOSING ADULT GH DEFICIENCY 37
Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement 37
Development and internal validation of a predictive score for the diagnosis of central adrenal insufficiency when morning cortisol is in the grey zone 37
Neuroendocrine response to diclofenac in healthy subjects: a pilot study. 37
Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy 37
Trabecular Bone Score as an Index of Bone Fragility in Patients with Acromegaly: A Systematic Review and Meta-Analysis. 34
Disordini dell'accrescimento 34
Psychiatric disorders and anger in patients with controlled acromegaly 33
Physiopathology, Diagnosis, and Treatment of Hyperprolactinemia 32
Replacement therapy in adult with GHD: how to treat and monitor. 29
Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly 29
Radiomic Analysis in Pituitary Tumors: Current Knowledge and Future Perspectives 27
MRI Assessment of Cardiac Function and Morphology in Adult Patients With Growth Hormone Deficiency: A Systematic Review and Meta-Analysis 27
GHRH + arginine test and body mass index: do we need to review diagnostic criteria for GH deficiency? 26
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas 26
Positive metabolic impact of treatment with pegvisomant in an acromegalic patient 26
Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population 25
Totale 8.062
Categoria #
all - tutte 29.623
article - articoli 0
book - libri 0
conference - conferenze 1.263
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.886


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020410 0 0 0 0 0 0 0 95 135 76 73 31
2020/2021956 77 47 48 53 106 48 119 75 80 103 73 127
2021/20221.104 50 53 71 60 94 48 54 71 56 93 227 227
2022/20231.690 176 141 28 185 171 375 124 88 181 55 107 59
2023/2024762 89 117 31 56 36 62 46 82 19 54 59 111
2024/20251.330 22 169 69 232 579 158 64 37 0 0 0 0
Totale 8.320